CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy

Luo H, Li T, Meng F, Hong Z, Cao Y, Wang G, Huang L, Zhou X
У данной статьи нет абстракта.
Cancer biology & medicine, 2025-05-08